Anti Cd 20 Ocrevus denied as not medically necessary by Humana?

Humana's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Ocrelizumab as Not Medically Necessary

A medical-necessity denial from Humana means Humana's clinical reviewer concluded that the submitted documentation did not satisfy the criteria in Humana's coverage policy for ocrelizumab (Ocrevus). This does not mean your neurologist's judgment is wrong — it means the information Humana received was not sufficient to meet the specific checklist in its policy. Medical-necessity is the most common appeal ground for high-efficacy MS therapies, and it is among the most frequently overturned denial types when a well-documented appeal is submitted.

## Why This Denial Is Appealable

Humana's medical-necessity criteria must align with evidence-based clinical standards; they cannot simply be more restrictive than what recognized guidelines and the FDA label support. If your clinical profile meets the criteria set out in Humana's own policy — or if your neurologist can demonstrate that deviation from a specific criterion is clinically justified — the denial should be overturned. External reviewers assessing medical-necessity appeals are required to apply recognized clinical evidence standards, which often differ from an insurer's internal policy.

## Your Federal Appeal Rights

• Internal appeal: ERISA §503 and ACA §2719 guarantee a full-and-fair internal review. File within the deadline shown in your denial letter.
• External review: After exhausting internal remedies, an independent external review is available under ACA §2719, generally within approximately four months of final internal denial.
• Expedited track: Patients who are currently being treated or face imminent clinical deterioration should request expedited review; decisions are typically required within 72 hours.

## Documentation to Gather

1. Humana's written coverage policy for ocrelizumab — this is the checklist your appeal must answer. Request it specifically. 2. Neurologist's medical-necessity letter addressing each of Humana's criteria in sequence, using the exact language from the policy where possible. 3. Diagnosis confirmation — MRI reports (with radiologist reads), clinical notes establishing the MS diagnosis, classification, and current disease-activity level. 4. Prior disease-modifying therapy history — a dated log of every DMT previously used, with start and end dates and documented reasons for each transition (failure, intolerance, or contraindication). 5. Functional and disability assessments — any documented measure of clinical severity, recorded in the chart by the treating neurologist, that establishes the impact of the disease on daily function. 6. Lab and monitoring results — relevant baseline and follow-up results your neurologist ordered in connection with this prescription.

## Criteria-Mapping Approach

Obtain Humana's policy and list every coverage criterion in a left column. In the right column, cite the specific chart entry, date, and clinician note that satisfies each requirement. For criteria tied to eligibility thresholds (such as diagnostic classification or prior treatment requirements), cite the exact language from the FDA-approved prescribing information and your neurologist's documentation rather than any number from memory. This structured mapping prevents reviewers from finding unanswered criteria and issuing a second denial on a different ground.

## Next Step

Request both the denial letter and Humana's complete written coverage policy before drafting the appeal. Your neurologist's office should review the policy's criteria checklist and draft the medical-necessity letter specifically to answer each item.